Blueprint Medicines Initiates Dosing In Liver Cancer Study
Zacks Investment Research | Jan 06, 2020 10:26PM ET
Blueprint Medicines Corporation (NASDAQ:BPMC) along with China’s CStone Pharmaceuticals announced that it has dosed the first patient in a phase Ib/II study evaluating its FGFR4 inhibitor fisogatinib in combination with CStone’s PD-L1 inhibitor CS1001 for the treatment of locally advanced or metastatic hepatocellular carcinoma (HCC), a type of liver cancer. The objective of this program is to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of the combination regimen.
The above-mentioned study will assess the potential of two complementary treatment approaches, namely precision therapy and immuno-oncology therapy to enhance anti-tumor activity in the given patient population.
Blueprint Medicines has a collaboration agreement with CStone for developing and commercializing fisogatinib across Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combo regimes.
Per the company, data from the ongoing phase I study, published on Oct 1, 2019, showed that treatment with fisogatinib monotherapy was well-tolerated in patients with heavily pretreated advanced HCC.
Notably, the FDA has granted an orphan drug designation to fisogatinib for the treatment of HCC.
Shares of Blueprint Medicines have surged 30% in the past year against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.